A61K 47/68035
The drug being a pyrrolobenzodiazepine
Official title: {the drug being a pyrrolobenzodiazepine}
A61K47/68035 (The drug being a pyrrolobenzodiazepine) appears on 263 US grants and 514 published applications in this corpus.
Search patents in A61K- Granted patents
- 263
- Published applications
- 514
- Assignees
- 125
- Inventors
- 847
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 1 | 3 |
| 2013 | 0 | 5 |
| 2014 | 3 | 13 |
| 2015 | 11 | 16 |
| 2016 | 18 | 43 |
| 2017 | 16 | 40 |
| 2018 | 36 | 48 |
| 2019 | 22 | 51 |
| 2020 | 34 | 47 |
| 2021 | 21 | 42 |
| 2022 | 20 | 54 |
| 2023 | 32 | 37 |
| 2024 | 12 | 45 |
| 2025 | 26 | 36 |
| 2026 | 11 | 32 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Antigen-binding protein constructs and uses thereof1 Sep 2026US 12,721,901 B2Mythic Therapeutics, Inc.
- Anti-CD45 antibody drug conjugates and uses thereof1 Sep 2026US 12,723,097 B2Regeneron Pharmaceuticals, Inc.
- Molecules that bind to CD66e polypeptides11 Aug 2026US 12,703,760 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (TDC)14 Jul 2026US 12,678,474 B2
- Combination therapy with antibody-drug conjugates and hyaluronidases14 Jul 2026US 12,678,492 B2Halozyme, Inc.
- Antibody conjugate, and uses thereof24 Sep 2026US 2026/0284219 A1Acepodia Biotechnologies Ltd.
- Combination therapy with antibody-drug conjugates and hyaluronidases17 Sep 2026US 2026/0273030 A1Halozyme, Inc.
- Gfra2 as a candidate immunotherapeutic target in neuroblastoma and ewing sarcoma17 Sep 2026US 2026/0274969 A1Texas Tech University System
- Cthrc1 is a novel immune checkpoint molecule in colorectal cancer10 Sep 2026US 2026/0265355 A1MaineHealth
- Anti-ceacam5/6 dual-binding antibodies3 Sep 2026US 2026/0258125 A1Nona Biosciences (Suzhou) Co., Ltd.
Most cited
By later US patents
- Pyrrolobenzodiazepines used to treat proliferative diseases139US 8,697,688 B2Seattle Genetics, Inc. · 2014
- Targeted pyrrolobenzodiazapine conjugates74US 9,242,013 B2MedImmune, LLC · 2016
- Anti-CD38 antibodies for the treatment of cancer73US 8,153,765 B2Sanof Aventis · 2012
- Cytotoxic benzodiazepine derivatives41US 8,765,740 B2ImmunoGen, Inc. · 2014
- Pyrrolobenzodiazepines and conjugates thereof32US 9,889,207 B2MedImmune, LLC · 2018